



**HAL**  
open science

## Resistance to third-generation cephalosporins in *Escherichia coli* in the French community: The times they are a-changin'?

Audrey Jeanvoine, H el ene Bouxom, Joel Leroy, Houssein Gbaguidi-Haore, Xavier Bertrand, C eline Slekovec

### ► To cite this version:

Audrey Jeanvoine, H el ene Bouxom, Joel Leroy, Houssein Gbaguidi-Haore, Xavier Bertrand, et al.. Resistance to third-generation cephalosporins in *Escherichia coli* in the French community: The times they are a-changin'?. *International Journal of Antimicrobial Agents*, 2020, pp.105909. 10.1016/j.ijantimicag.2020.105909 . hal-02541479

HAL Id: hal-02541479

<https://hal.science/hal-02541479v1>

Submitted on 22 Aug 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destin ee au d ep ot et  a la diffusion de documents scientifiques de niveau recherche, publi es ou non,  emanant des  tablissements d'enseignement et de recherche fran ais ou  trangers, des laboratoires publics ou priv es.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

1 **Resistance to third-generation cephalosporins in *Escherichia coli* in the French**  
2 **community, The Times They Are A-Changin'?**

3

4 Audrey Jeanvoine<sup>1,2\*</sup>, H el ene Bouxom<sup>1,3</sup>, Joel Leroy<sup>3,4</sup>, Houssein Gbaguidi-Haore<sup>1,2</sup>,

5 Xavier Bertrand<sup>1,2,3,4</sup>, C eline Slekovec<sup>2,3,4</sup>

6

7 <sup>1</sup>Hygi ne Hospitali re, Centre Hospitalier R gional Universitaire, Besan on, France

8 <sup>2</sup>UMR 6249 Chrono-environnement, Universit  de Bourgogne-Franche-Comt , Besan on,

9 France

10 <sup>3</sup>CPias Bourgogne-Franche-Comt , Centre Hospitalier R gional Universitaire, Besan on,

11 France

12 <sup>4</sup>Observatoire de la Consommation Antibiotique et de la R sistance bact rienne OSCAR,

13 Centre Hospitalier R gional Universitaire, Besan on, France

14

15

16

17 **\* Corresponding author**

18 Audrey Jeanvoine, [ajeavoine@chu-besancon.fr](mailto:ajeavoine@chu-besancon.fr)

19 Hygi ne Hospitali re, Centre Hospitalier R gional Universitaire, 3 boulevard Fleming,

20 Besan on, Cedex 25030, France.

21 Tel: (33) 3 70 63 22 71

22 Fax: (33) 3 70 63 23 64

23

24 **Running title:** Resistance of *E. coli* to third-generation cephalosporins in outpatients

25 **Abstract**

26 **Introduction.** Since the early 2000s, *E. coli* resistance to third-generation cephalosporins  
27 (3GCs) has been increasing in all European countries, mainly due to the spread of extended  
28 spectrum  $\beta$ -lactamases (ESBL). We present here a retrospective study that combines  
29 resistance of *E. coli* to 3GCs and quinolones and the antibiotic use in the community in a  
30 region of Northeastern France.

31 **Materials and Methods.** Since 2012, we conducted an observational surveillance of  
32 antimicrobial resistance and antibiotic use in the community: data of antibiotic resistance in  
33 *E. coli* isolates were collected from 11 private laboratories, and consumption data from the  
34 three main healthcare insurances.

35 **Results.** A significant decrease of resistance prevalence to 3GCs (from 5.6 to 3.9%,  $p <$   
36 0.001), nalidixic acid (16.7 to 14.8%,  $p = 0.004$ ) and ciprofloxacin (10.9 to 8.1%,  $p < 0.001$ )  
37 was reported between 2015 and 2017. Although the total antibiotic consumption did not  
38 vary significantly between 2012 and 2017, we observed a decrease of the consumption of  
39 3GCs (-32%,  $p < 0.001$ ) and fluoroquinolones (-25%,  $p < 0.001$ ).

40 **Conclusion.** We report here a decrease of the prevalence of *E. coli* isolates resistant to 3GCs  
41 and quinolones in outpatients in a context of significant decreasing consumptions of these  
42 two antibiotic classes.

43

44 **Keywords:** *E. coli*; third-generation cephalosporins; quinolones; resistance; outpatients.

45

46

47 **1. Introduction**

48 High rates of antimicrobial resistance in *Escherichia coli* are an important global  
49 public health concern [1]. Indeed, *E. coli* constitutes a major cause of both community-onset  
50 and hospital-acquired infections [2]. Since the early 2000s, *E. coli* resistance to third-  
51 generation cephalosporins (3GCs) has been increasing in hospital and community settings of  
52 all European countries, mainly due to the spread of extended spectrum  $\beta$ -lactamases (ESBL)  
53 [1,3,4]. In 2017, EARS-net report showed that the rate of resistance of *E. coli* to 3GCs  
54 reached 14.9 % in bacteremias in hospital setting and upward trends were observed in  
55 almost all European countries in the last decade [1]. Besides these hospital data, several  
56 surveillances have also reported an increasing trend of resistance to 3GCs in *E. coli* from the  
57 community [5,6]. This spread combines dissemination of epidemic clones such as ST131 -  
58 C1/H30-R and C2/H30-Rx clades, as well as horizontal transfers of plasmid-borne *bla*<sub>ESBL</sub> [7].  
59 The possibility that ESBL rates reach that of penicillinase within this species is clearly a  
60 matter of major concern.

61 ESBL-producing *E. coli* isolates are often resistant to other antibiotics such as  
62 fluoroquinolones and aminoglycosides, further complicating the management of patients  
63 infected with ESBL-producing *Enterobacteriaceae* [6,7]. Indeed, combined resistance to  
64 3GCs, fluoroquinolones, and aminoglycosides was 6.3 % in 2017 in the EU, but did not  
65 significantly change during the period 2014–2017 [1]. Moreover, up to 70 % of ESBL-  
66 producing isolates were resistant to fluoroquinolones in community-onset infections [6]. The  
67 spread of ESBL-producing *E. coli* within the community is mainly driven by antimicrobial  
68 exposure, notably previous use of fluoroquinolones and oral 3GCs, which have a high  
69 ecological impact [8]. In that context, we implemented in our region an antimicrobial  
70 resistance stewardship program that monitored the antibiotic use in outpatients.

71            We present here a retrospective study that combines the resistance of *E. coli* to 3GCs

72 and quinolones and the antibiotic use in the community in a region of Northeastern France.

73

74

75 **2. Materials and methods**

76 Since 2012, we conducted an observational surveillance (the OSCAR network) of  
77 antimicrobial resistance and antibiotic use in the community in Franche-Comté region, a  
78 Northeastern area of France with 1.2 million inhabitants.

79 3GCs and quinolones (nalidixic acid and ciprofloxacin) resistance data were collected  
80 during six years (2012-2017) from eleven private laboratories. All resistance data concerning  
81 nursing homes or clinics were excluded. For one patient, one isolate per susceptibility profile  
82 and per year was considered.

83 Antimicrobial consumption data were provided by the three main healthcare  
84 insurances of Franche-Comté and their beneficiaries represented 88% of the total  
85 population. These antibiotic reimbursement data for ambulatory care, based on antibiotics  
86 dispensed in community pharmacies, were available since 2012. The consumption data were  
87 expressed in defined daily dose (DDD) per 1000 beneficiaries per day for each antibiotic for  
88 systemic use (ATC group J01): tetracyclines (J01A),  $\beta$ -lactams (J01C and J01D), sulfamide and  
89 trimethoprim (J01E), macrolides (J01F), aminoglycosides (J01G), fluoroquinolones (J01M)  
90 and associations and other antibiotics (J01R+J01X) [9].

91 We tested the variation in the prevalence of *E. coli* isolates resistant to 3GCs, nalidixic  
92 acid, and ciprofloxacin, using the  $\chi^2$  test. The trend of consumption of each antibiotic class  
93 over the period 2012 to 2017 was tested by using a negative binomial model for which the  
94 DDD were considered as counting data. The relative change, also calculated here, consists of  
95 the variation of consumption of each antibiotic class between the two years 2012 and 2017.

96

97

98 **3. Results**

99 **3.1 Antimicrobial resistance in *E. coli***

100 A total of 34,767 *E. coli* isolates have been tested for their susceptibility between 2012 and  
101 2017. Trend in resistance prevalence of *E. coli* to 3GCs, nalidixic acid, and ciprofloxacin, are  
102 shown in Figure 1a. Resistance rate for 3GCs was 3.9% in 2012, reached 5.9% in 2015 and  
103 significantly decreased between 2015 and 2017, from 5.9 to 4.2% ( $p < 0.001$ ). Although the  
104 evolution of the prevalence of resistance to nalidixic acid differed from that to 3GCs and  
105 ciprofloxacin between 2012 and 2015, a significant decrease of the prevalence of resistance  
106 to quinolones was also reported between 2015 and 2017, from 16.7 to 14.8% for nalidixic  
107 acid ( $p = 0.004$ ) and from 10.9 to 8.1% for ciprofloxacin ( $p < 0.001$ ). Among *E. coli* isolates  
108 resistant to 3GCs collected between 2012 and 2017, the prevalence of nalidixic acid and  
109 ciprofloxacin resistance decreased in parallel between 2015 and 2017, from 73.8 to 64.2%,  
110 and from 66.8 to 52.9%, respectively (Figure 1b).

111

112 **3.2 Antibiotics consumption**

113 Although the total antibiotic consumption did not vary significantly between 2012 and 2017,  
114 the use of penicillins (J01C), and that of the broad-spectrum penicillins (J01CA) such as  
115 amoxicillin (J01CA04), increased significantly ( $p < 0.001$ ) over the study period (Table 1).  
116 Except for tetracyclines (J01A) and associations and other antibiotics (J01R+J01X), we found  
117 a significant downward trend of consumption for the others studied group of antibiotics  
118 (Table 1). We notably observed a decrease of the 3GCs (J01DD, -32.1%,  $p < 0.001$ ) and  
119 fluoroquinolones consumption (J01M, -25.5%,  $p < 0.001$ ) over the study period (Table 1,  
120 Figure 1a).

121

#### 122 4. Discussion

123 After several years of constant rise, we report here a significant decrease of the  
124 prevalence of *E. coli* resistant to 3GCs and quinolones in outpatients from Franche-Comté  
125 between 2015 and 2017. Regarding the resistance to 3GCs, our results confirm those  
126 collected by another French surveillance network (Medqual) which nevertheless reported a  
127 lower decrease between 2015 and 2017 (from 4.5% in 2015 to 4% in 2017 *versus* 5.9% to  
128 4.2% in Franche-Comté) [10]. These trends observed in the community coincided with those  
129 recorded in EARS-net database, the national survey of *E. coli* isolated from blood culture in  
130 French hospitals (11% in 2015 to 10.2% in 2017) [1]. Although this national downward trend  
131 was not significant, the decrease reported in Franche-Comté could be more general in  
132 France.

133 Concerning fluoroquinolones, the decrease of resistance reported here was also highlighted  
134 by EARS-net data in France (from 17.7% in 2015 to 15% in 2017) [1]. The same trend was  
135 described by the Medqual network in community-onset infections for nalidixic acid.

136 However, the decrease of the resistance rate of ciprofloxacin in *E. coli* was less pronounced,  
137 from 10.1% in 2015 to 9.6% in 2017 *versus* 10.9% to 8.1% in Franche-Comté [10]. According  
138 to other studies, we described here high resistance rates of quinolones in isolates resistant  
139 to 3GCs [6,11].

140

141 Interestingly, the decrease of the prevalence of *E. coli* resistant to 3GCs in  
142 community-onset infections reported here occurred in a context of a significant decrease of  
143 the consumption of 3GCs and fluoroquinolones, despite a significant increase of penicillins  
144 consumption. Many studies have described the high-ecological impact of 3GCs and  
145 fluoroquinolones. For instance, recent phylogenic studies using whole genome sequencing



146 identified the most recent common ancestor of successful epidemic clones, thus strongly  
147 suggesting that fluoroquinolones had played an important role in the global expansion of the  
148 major pathogens *Escherichia coli* ST131 H30-Rx, methicillin-resistant *Staphylococcus aureus*  
149 EMRSA-15, *Pseudomonas aeruginosa* ST235 in the mid-1980s, and that of *Clostridium*  
150 *difficile* 027 in the early 1990s [12–15].

151

152           Although this is not statistically demonstrated, the decrease of the use of  
153 fluoroquinolones and 3GCs, which began in 2013 in our region, presumably played a major  
154 role in the trend of resistance to 3GCs among community *E. coli* isolates. However, the  
155 reducing consumption of antibiotics is not immediately followed by the decrease of  
156 antibiotic resistance. Some studies reported that once the resistance to an antimicrobial is  
157 well established in a population of *E. coli*, a reduction in the use of that antimicrobial is  
158 unlikely to influence to resistance rates in the short-to-medium term [2,16]. This could be  
159 explained by two effects. The first one may be due to the prolonged carriage of multidrug-  
160 resistant *E. coli* even in the absence of antimicrobial selection pressure, described for *E. coli*  
161 ST131 [17]. Hence, it may take several years to achieve a sufficient patient turnover and to  
162 observe the effect of antibiotic use reduction [16]. The second one is the nonlinear  
163 relationship between the antibiotic use and resistance ; other parameters could be involved  
164 such as dissemination of resistant strains by cross-transmission [18]. A recent study has  
165 calculated antibiotic consumption thresholds below which the resistance rates are  
166 independent from the consumption. For instance, minimum thresholds were estimated for  
167 selected antibiotics and the rates of ESBL-producing or cefepime-resistant *E. coli* [18].

168

169           This study has several limitations. First, our data did not establish a significant  
170 relationship between the decrease of antibiotic resistance rate and their consumption. Then,  
171 we missed the genotyping data that could have allowed the understanding of the decrease  
172 of resistance reported here. However, we could speculate that the decrease in prevalence of  
173 the major multidrug-resistant clone *E. coli* ST131 H30-Rx participated, at least in part, to the  
174 decrease of the resistance in the species. OSCAR network surveillance must be continued to  
175 confirm the trend in resistance prevalence and antibiotics consumption reported here.

176

177

178 **5. Conclusion**

179 We report here a decrease of the prevalence of *E. coli* isolates resistant to 3GCs and to  
180 quinolones in a context of decreasing consumptions of these two antibiotic classes. The  
181 stewardship programs can efficiently decrease the antimicrobial resistance, making the  
182 progression to multi-resistance not inevitable. However, actions improving antimicrobial  
183 prescription should be continuous because of their delayed effect.

184

185 **Acknowledgments**

186 We thank the private laboratory group CBM25, Centre de Biologie médicale, who enabled  
187 the use of its antibiotic resistance data.

188

189 **Declarations**

190 **Funding.** This study received a partial grant from the Regional Health Agency (ARS  
191 Bourgogne-Franche-Comté).

192 **Competing Interests:** None

193 **Ethical Approval:** Not required

194

195 **Author contributions.** Conceived and designed the experiments: XB, CBS, and JL. Performed  
196 the experiments: CBS, HB, and HGH. Analyzed the data: CBS, HB, AJ, and HGH. Wrote the  
197 paper: AJ, CBS, and XB.

198

199

200 **References**



- 201 [1] European centre for disease prevention and control. Surveillance of antimicrobial  
202 resistance in Europe 2017, [https://www.ecdc.europa.eu/en/publications-  
204 data/surveillance-antimicrobial-resistance-europe-2017](https://www.ecdc.europa.eu/en/publications-<br/>203 data/surveillance-antimicrobial-resistance-europe-2017); 2017 [accessed 19 October  
205 2019].
- 206 [2] Stapleton PJ, Lundon DJ, McWade R, Scanlon N, Hannan MM, O’Kelly F, *et al.* Antibiotic  
207 resistance patterns of *Escherichia coli* urinary isolates and comparison with antibiotic  
208 consumption data over 10 years, 2005–2014. *Ir J Med Sci* 2017; 186:733–41.  
<https://doi.org/10.1007/s11845-016-1538-z>.
- 209 [3] Cantón R, Novais A, Valverde A, Machado E, Peixe L, Baquero F, *et al.* Prevalence and  
210 spread of extended-spectrum  $\beta$ -lactamase-producing *Enterobacteriaceae* in Europe.  
211 *Clin Microbiol Infect* 2008; 14:144–53. [https://doi.org/10.1111/j.1469-  
213 0691.2007.01850.x](https://doi.org/10.1111/j.1469-<br/>212 0691.2007.01850.x).
- 214 [4] Hawser SP, Bouchillon SK, Hoban DJ, Badal RE, Canton R, Baquero F. Incidence and  
215 antimicrobial susceptibility of *Escherichia coli* and *Klebsiella pneumoniae* with  
216 extended-spectrum-lactamases in community- and hospital-associated intra-abdominal  
217 infections in Europe: results of the 2008 study for monitoring antimicrobial resistance  
218 trends (SMART). *Antimicrob Agents Chemother* 2010; 54:3043–6.  
<https://doi.org/10.1128/AAC.00265-10>.
- 219 [5] Boix-Palop L, Xercavins M, Badía C, Obradors M, Riera M, Freixas N, *et al.* Emerging  
220 extended-spectrum  $\beta$ -lactamase-producing *Klebsiella pneumoniae* causing community-  
221 onset urinary tract infections: a case–control–control study. *Int J Antimicrob Agents*  
222 2017; 50:197–202. <https://doi.org/10.1016/j.ijantimicag.2017.03.009>.

- 223 [6] Chervet D, Lortholary O, Zahar JR, Dufougeray A, Pilmis B, Partouche H. Antimicrobial  
224 resistance in community-acquired urinary tract infections in Paris in 2015. *Med Mal*  
225 *Infect* 2018; 48:188–92. <https://doi.org/10.1016/j.medmal.2017.09.013>.
- 226 [7] Stoesser N, Sheppard AE, Pankhurst L, De Maio N, Moore CE, Sebra R, *et al.*  
227 Evolutionary history of the global emergence of the *Escherichia coli* epidemic clone  
228 ST131. *MBio* 2016; 7:e02162. <https://doi.org/10.1128/mBio.02162-15>.
- 229 [8] Paterson DL. “Collateral Damage” from cephalosporin or quinolone antibiotic therapy.  
230 *Clin Infect Dis* 2004; 38:S341–5. <https://doi.org/10.1086/382690>.
- 231 [9] World Health Organization. Anatomical Therapeutic Chemical (ATC) classification index  
232 with defined daily doses (DDDs),  
233 <http://apps.who.int/medicinedocs/en/d/Js2202e/5.html>, Norway; 2001 [accessed 29  
234 October 2019].
- 235 [10] ONERBA. 2017 Rapport d’activité : Annual report,  
236 <http://onerba.org/publications/rapports-onerba/>; 2018 [accessed 29 October 2019].
- 237 [11] Azargun R, Sadeghi MR, Soroush Barhaghi MH, Samadi Kafil H, Yeganeh F, Ahangar  
238 Oskouee M, *et al.* The prevalence of plasmid-mediated quinolone resistance and ESBL-  
239 production in *Enterobacteriaceae* isolated from urinary tract infections. *Infect Drug*  
240 *Resist* 2018; 11:1007–14. <https://doi.org/10.2147/IDR.S160720>.
- 241 [12] Ben Zakour NL, Alsheikh Hussain AS, Ashcroft MM, Khanh Nhu NT, Roberts LW, Stanton  
242 Cook M, *et al.* Sequential acquisition of virulence and fluoroquinolone resistance has  
243 shaped the evolution of *Escherichia coli* ST131. *MBio* 2016; 7:e00347-16.  
244 <https://doi.org/10.1128/mBio.00347-16>.

- 245 [13] He M, Miyajima F, Roberts P, Ellison L, Pickard DJ, Martin MJ, *et al.* Emergence and  
246 global spread of epidemic healthcare-associated *Clostridium difficile*. *Nat Genet* 2013;  
247 45:109–13. <https://doi.org/10.1038/ng.2478>.
- 248 [14] Holden MT, Hsu LY, Kurt K, Weinert LA, Mather AE, Harris SR, *et al.* A genomic portrait  
249 of the emergence, evolution, and global spread of a methicillin-resistant  
250 *Staphylococcus aureus* pandemic. *Genome Res* 2013; 23:653–64.  
251 <https://doi.org/10.1101/gr.147710.112>.
- 252 [15] Treepong P, Kos VN, Guyeux C, Blanc DS, Bertrand X, Valot B, *et al.* Global emergence of  
253 the widespread *Pseudomonas aeruginosa* ST235 clone. *Clin Microbiol Infect* 2018;  
254 24:258–66. <https://doi.org/10.1016/j.cmi.2017.06.018>.
- 255 [16] Muller A, Romand K, Suplisson D, Nattero JF, Leroy J, Bertrand X. Impact of a long-term  
256 antibiotic stewardship program targeting fluoroquinolones in a French local hospital.  
257 *Med Mal Infect* 2019; 49:442-6. <https://doi.org/10.1016/j.medmal.2018.10.006>.
- 258 [17] Overdeest I, Haverkate M, Veenemans J, Hendriks Y, Verhulst C, Mulders A, *et al.*  
259 Prolonged colonisation with *Escherichia coli* O25:ST131 versus other extended-  
260 spectrum beta-lactamase-producing *E. coli* in a long-term care facility with high  
261 endemic level of rectal colonisation, the Netherlands, 2013 to 2014. *Eurosurveillance*  
262 2016; 21. <https://doi.org/10.2807/1560-7917.ES.2016.21.42.30376>.
- 263 [18] López-Lozano JM, Lawes T, Nebot C, Beyaert A, Bertrand X, Hocquet D, *et al.* A  
264 nonlinear time-series analysis approach to identify thresholds in associations between  
265 population antibiotic use and rates of resistance. *Nat Microbiol* 2019; 4:1160-72.  
266 <https://doi.org/10.1038/s41564-019-0410-0>.

267 **Figure captions**

268 **Figure 1.** Resistance prevalence of *E. coli* isolated from community-onset infections to third-  
269 generation cephalosporins and quinolones between 2012 and 2017 in Franche-Comté  
270 (Northeastern France). **(a)** Trend in resistance rate of *E. coli* isolated from community-onset  
271 infections to third-generation cephalosporins (3GCs), nalidixic acid (NA) and ciprofloxacin  
272 (CIP) associated to 3GCs and quinolones consumption between 2012 and 2017 in the  
273 Northeastern France. Prevalence of resistance to 3GCs, NA and CIP are represented by dark  
274 grey, light grey and black lines, respectively. The prevalence of *E. coli* resistant to these  
275 antibiotics decreased between 2015 and 2017 ( $\chi^2$  test). Consumptions of 3GCs and  
276 fluoroquinolones (FQs) are represented by dark grey and light grey bars, respectively. **(b)**  
277 Trend in resistance rate to nalidixic acid (NA) and ciprofloxacin (CIP) of *E. coli* isolates resistant  
278 to third-generation cephalosporins (3GCs-R) between 2012 and 2017 in the Northeastern  
279 France. The bars represent the number of *E. coli* isolates 3GCs-R between 2012 and 2017.  
280 Light grey and dark grey lines represent the percentage of 3GCs-R *E. coli* isolates resistant to  
281 NA and CIP, respectively.





**Table 1:** Consumption of antibiotics for the treatment of community-onset infections in the Northeastern France between 2012 and 2017.

Antibiotic class	Antibiotic consumption (DDD / 1000 beneficiaries / day)						Relative change <sup>1</sup> (%)	Trend <sup>2</sup> (p)
	2012	2013	2014	2015	2016	2017		
<b>J01A - tetracyclines</b>	2.57	2.93	2.64	2.47	2.61	2.52	- 1.8	0.208
<b>J01C - <math>\beta</math>-lactams-penicillins</b>	14.93	18.53	18.07	18.19	19.28	18.47	23.7	0.020*
<b>J01CA - broad spectrum penicillins</b>	7.92	10.38	10.25	10.68	11.69	11.68	47.5	< 0.001*
<b>J01CR - penicillins associations</b>	6.40	7.52	7.18	7.04	7.19	6.39	- 0,20	0.720
<b>J01CR02 - amoxicillin-clavulanic acid</b>	NA	NA	NA	7.03	7.18	6.38	NC	NC
<b>J01D - other <math>\beta</math>-lactams</b>	2.73	2.77	2.64	2.42	2.24	1.75	- 35.9	0.001*
<b>J01DB - first-generation cephalosporins</b>	0.22	0.035	0.16	0.015	0.015	0.007	- 96.8	< 0.001*
<b>J01DC - second-generation cephalosporins</b>	0.59	0.87	0.56	0.59	0.52	0.43	- 26.8	0.011*
<b>J01DD - third-generation cephalosporins</b>	1.92	1.86	1.91	1.81	1.70	1.30	- 32.1	0.001*
<b>intravenous 3GCs</b>	0.12	0.15	0.14	0.15	0.14	0.13	13.6	0.327
<b>per os 3GCs</b>	1.80	1.71	1.77	1.66	1.56	1.17	- 35.1	0.001*
<b>J01E- sulfamide and trimethoprim</b>	0.67	0.81	0.77	0.37	0.36	0.35	- 47.3	0.001*
<b>J01F-macrolides</b>	3.47	3.87	3.41	3.49	3.46	3.08	- 11.4	0.027*
<b>J01FG01-pristinamycin</b>	NA	NA	NA	0.98	0.90	0.90	NC	NC
<b>J01G- aminoglycosides</b>	0.04	0.042	0.035	0.033	0.031	0.025	- 36.4	< 0.001*
<b>J01M- fluoroquinolones</b>	1.56	1.71	1.57	1.38	1.30	1.16	- 25.5	< 0.001*
<b>intravenous fluoroquinolones</b>	0.00051	0.0007	0.00027	0.00049	0.00013	0.00052	- 3.0	0.438
<b>per os fluoroquinolones</b>	1.56	1.71	1.57	1.38	1.30	1.16	- 25.5	< 0.001*
<b>J01R+J01X - Associations and other antibiotics</b>	0.52	1.05	0.98	1.0	0.96	0.87	67.7	0.290
<b>Total</b>	26.91	31.70	30.10	29.35	30.24	28.24	4.9	0.905

NA: not available, NC: not calculated, \*: significant trend (p < 0.05)

<sup>1</sup>Relative change consists of the variation of consumption of each antibiotic class between the two years 2012 and 2017.

<sup>2</sup>The trend of consumption of each antibiotic class was determined over the period 2012 to 2017 by using a negative binomial model